Merck no longer in talks to acquire Revolution Medicines

The companies had negotiated a deal worth approximately 30 billion USD. The attack on the "undruggable" target RAS Revolution's experimental drugs aim to block the disease driver RAS, thereby combating common cancers such as lung, pancreatic, and colorectal cancers, which have been considered difficult to treat. RAS refers to a family of genes and the resulting proteins that play a crucial role in human cell biology. For decades, scientists have been researching therapies that target RAS, as the protein plays a key role in many cancers...